Christopher Leamon
Directeur Technique/Scientifique/R&D chez FUSN PHAR
Profil
Christopher P.
Leamon is currently the Chief Scientific Officer at Fusion Pharmaceuticals, Inc. He previously worked as the Executive Director-Radioligand Drug Discovery at Novartis Institutes for Biomedical Research, Inc., Principal at Glaxo Wellcome Plc, Vice President-Research at Endocyte, Inc., and Vice President-Discovery Research at Advanced Accelerator Applications USA, Inc. He received his undergraduate degree from Baldwin-Wallace College and his doctorate from Purdue University.
Postes actifs de Christopher Leamon
| Sociétés | Poste | Début |
|---|---|---|
| FUSN PHAR | Directeur Technique/Scientifique/R&D | 02/11/2021 |
Anciens postes connus de Christopher Leamon
| Sociétés | Poste | Fin |
|---|---|---|
Advanced Accelerator Applications USA, Inc.
 Advanced Accelerator Applications USA, Inc. Medical SpecialtiesHealth Technology Part of Novartis AG, Advanced Accelerator Applications USA, Inc. develops, produces, and commercializes MNM diagnostic and therapeutic products. The company is based in New York, NY. | Corporate Officer/Principal | - |
| Glaxo Wellcome Plc | Corporate Officer/Principal | - |
Novartis Institutes for Biomedical Research, Inc.
 Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
| ENDOCYTE, INC. | Directeur Technique/Scientifique/R&D | - |
Formation de Christopher Leamon
| Purdue University | Doctorate Degree |
| Baldwin-Wallace College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Endocyte, Inc.
 Endocyte, Inc. Pharmaceuticals: MajorHealth Technology Endocyte, Inc. engages in the development of targeted therapies for the treatment of cancer and inflammatory diseases. It uses a proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies. Its small molecule drug conjugates are actively target receptors that are over-expressed on diseased cells. The company was founded by P. Ron Ellis and Philip S. Low on December 6, 1995 and is headquartered in West Lafayette, IN. | Health Technology |
| Glaxo Wellcome Plc | Health Technology |
Fusion Pharmaceuticals, Inc.
 Fusion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Fusion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops GMP manufacturing of radiopharmaceuticals for the diagnosis and treatment of disease. The company was founded by John Vaillant in 2014 and is headquartered in Hamilton, Canada. | Health Technology |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Commercial Services |
Advanced Accelerator Applications USA, Inc.
Advanced Accelerator Applications USA, Inc. Medical SpecialtiesHealth Technology Part of Novartis AG, Advanced Accelerator Applications USA, Inc. develops, produces, and commercializes MNM diagnostic and therapeutic products. The company is based in New York, NY. | Health Technology |
